Filter
8995
Filtered Results: 8995
Text search:
medicines
Featured
Recommendations
777
New Publications
2199
Language
Document type
No document type
4799
Studies & Reports
1575
Guidelines
1191
Manuals
446
Strategic & Response Plan
276
Fact sheets
254
Training Material
179
Situation Updates
95
Resource Platforms
51
Infographics
44
Brochures
35
Online Courses
26
Videos
21
App
3
Countries / Regions
India
401
Global
342
Kenya
236
South Africa
201
Ethiopia
174
Africa
164
Uganda
159
Nepal
157
Sierra Leone
154
Western and Central Europe
148
Nigeria
147
Liberia
140
Latin America and the Carribbean
136
Malawi
118
Tanzania
117
Bangladesh
117
Ukraine
110
Zambia
108
Myanmar / Burma
105
Syria
98
Ghana
94
Rwanda
91
Congo, Democratic Republic of
79
Venezuela
75
Brazil
73
Philippines
68
Russia
68
Eastern Europe
67
Germany
66
Mozambique
59
Namibia
59
Zimbabwe
58
West and Central Africa
57
South–East Asia Region
55
Indonesia
48
East and Southern Africa
47
Senegal
46
Guinea
45
Asia
45
Burkina Faso
44
Haiti
44
Middle East and North Africa
43
Lesotho
42
Colombia
41
Yemen
40
South Sudan
38
Cambodia
38
Cameroon
34
Botswana
32
Peru
30
Paraguay
28
Eastern Europe and Central Asia
26
Benin
25
Eswatini/ Swaziland
23
Madagascar
21
Mali
19
Sudan
19
USA
18
Pakistan
18
Afghanistan
18
Lebanon
17
Vietnam
17
Thailand
16
Bolivia
16
Somalia
15
Angola
15
Western Pacific Region
15
Jordan
14
China
14
Central African Republic
14
Ecuador
14
Chile
14
Tajikistan
14
Moldova
14
Sri Lanka
13
Côte d’Ivoire / Ivory Coast
12
Argentina
12
Iraq
10
El Salvador
10
Georgia
10
North America
10
Spain
10
Albania
9
Southern Africa
9
Guinea-Bissau
8
Niger
8
North Macedonia
8
Mexico
8
Laos
8
Kyrgyzstan
8
United Kingdom
8
Palestine
7
Kazakhstan
7
Turkey
6
Egypt
6
Chad
6
Libya
6
Poland
6
Iran
6
France
6
Belarus
6
Saudi Arabia
5
Papua New Guinea
5
Guatemala
5
Jamaica
5
Morocco
4
Togo
4
Hungary
4
Burundi
4
Bhutan
4
Canada
4
Timor Leste/ East Timor
4
Estonia
4
Romania
4
Uzbekistan
4
Turkmenistan
4
Portugal
4
Gambia
3
Malaysia
3
Serbia
3
Greece
3
Fiji
3
Italy
3
Armenia
3
Qatar
3
Japan
3
Mauritius
3
Tunisia
3
Mauritania
2
Switzerland
2
Nicaragua
2
Other region
2
Mongolia
2
Congo-Brazzaville
2
Bulgaria
2
Lithuania
2
Australia
2
Gabon
2
South Korea
2
Israel
2
Bosnia and Herzegovina
2
Singapore
1
Dominican Republic
1
Austria
1
Honduras
1
Solomon Islands
1
Djibouti
1
Slovakia
1
Uruguay
1
Denmark
1
Belgium
1
Maldives
1
Norway
1
French Guyana
1
Latvia
1
Authors & Publishers
Publication Years
Category
Countries
3314
Clinical Guidelines
732
Public Health
524
Women & Child Health
389
Key Resources
252
Capacity Building
180
Pharmacy & Technologies
101
Annual Report MEDBOX
3
Toolboxes
COVID-19
867
Mental Health
769
HIV
671
TB
517
AMR
373
Pharmacy
281
Disability
276
Caregiver
273
NCDs
270
NTDs
257
Ebola
247
Planetary Health
244
Conflict
212
Rapid Response
209
Refugee
180
Global Health Education
139
Natural Hazards
87
Health Financing Toolbox
66
Zika
65
Specific Hazards
44
Social Ethics
41
Cholera
30
Polio
21
Health Financing
2
Typhoon
1
Using the WHO model list of essential medicines to update a national essential medicines list
Since 1977, WHO has been working with countries to design the package of essential ... as an integral component of treatment within the continuum of care, developing and disseminating the Model List of Essential Medicines (Model List). WHO is committed to supporting Member States in sharing best practices in selecting
essential medicines, and in developing processes for the selection of medicines for national essential medicines lists (national EMLs, or NEMLs) consistent with the evidence-based methods used for updating the WHO Model List.
The procurement of essential medicines and other health products is a critical function in support of the effective discharge of WHO’s mandate, and WHO values the importance of the quality of essential m... and health products that are supplied to countries. The first World Health Assembly in 1948 recognized the need to establish a procurement service at WHO, and recommended setting up an office “to give advice on the procurement of essential drugs, biological products and other medical supplies”.
This manual summarizes key issues related to the safety of NTD medicines and their administration, with a focus on essential medicines used in mass drug administration (MDA), also called preventive ...
Compilation of country case studies and best practices. World Health Report (2010) Background Paper, 25
A toolkit for pharmacists.
Emerging data show that medication errors and adverse events cause significant harm to patients’ health and
well-being. It is estimated that the burden of adverse events due to medicines is now comparable to that of
w...
Millions of people today cannot access medicine when they need to. This can be due to price, empty pharmacy shelves or other factors. Find out more about the situation and how the Index stimulates pharmaceutical companies to help turn it around.
World Journal of Pharmaceutical and Medical Research vol. 5 (2019) 3, 129-132
Pharmadex is a web-based tool that helps streamline and track medicines registration for a national drug regulatory authority. This tool was created by the USAID-funded Systems for Improved Access to Pharmaceutical and Services (SIAPS) Program imple...
This report reviews and analyses the Affordable Medicines Programme, which was introduced in Ukraine in April 2017 to provide patients with improved access to 23 outpatient medicines for the treatme...
Ukrainian Title:
УКРАЇНА: Еквівалентність лікарських засобів, зареєстрованих в Україні та інших країнах. Інформація для працівників охорони здоров'я та пацієнтів
To support t...
The Ukrainian refugee crisis has received prompt attention not only from concerned citizens outside Ukraine and the United Nations agencies but also from the European Commission (EC). For the first time, the Temporary Protection Directive 2001/55/EC was activated, enabling immediate access to health...
The pharmaceutical sector of any nation is responsible for providing society with quality medicines and other pharmaceutical services. According to the World Health Organization (WHO), Pharmaceuticals may constitute as much as 40% of the national he...
Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors
recommended
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and...
The availability of controlled medicines is crucial for patients requiring palliative care, pain relief and symptom management. Many individuals worldwide, especially in low- and middle-income countries, continue to experience limited access to thes...
On this website you can find information on high blood pressure, how to lower it and how blood pressure medicines work.
Background
Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordability of cardiovascular disease and hypertension ... to identify areas for improvement in access to medication treatment.
Methods and Results
We used the World Health Organization online repository of national essential medicines lists (EMLs) for 53 countries to transcribe the information on the inclusion of 12 cardiovascular disease/hypertension medications within each country's essential medicines list. Data on availability, price, and affordability were obtained from 84 surveys in 59 countries that used the World Health Organization's Health Action International survey methodology. We summarized and compared the indicators across lowest‐price generic and originator brand medicines in the public and private sectors and by country income groups. The average availability of the select medications was 54% in low‐ and lower‐middle‐income countries and 60% in high‐ and upper‐middle‐income countries, and was higher for generic (61%) than brand medicines (41%). The average patient median price ratio was 80.3 for brand and 16.7 for generic medicines and was higher for patients in low‐ and lower‐middle‐income countries compared with high‐ and upper‐middle‐income countries across all medicine categories. The costs of 1 month's antihypertensive medications were, on average, 6.0 days’ wage for brand medicine and 1.8 days’ wage for generics. Affordability was lower in low‐ and lower‐middle‐income countries than high‐ and upper‐middle‐income countries for both brand and generic medications.
Conclusions
The availability and accessibility of pharmaceuticals is an ongoing challenge for health systems. Low availability and high costs are major barriers to the use of and adherence to essential cardiovascular disease and antihypertensive medications worldwide, particularly in low‐ and lower‐middle‐income countries.
Heart failure (HF) is a leading global public health problem with >64 million prevalent cases globally. Patients with HF with reduced ejection fraction (HFrEF) from low- and middle-income countries experience a 22% to 58% higher 1-year mortality rate than those in high-income countries.1 Guideline-d...
The incidence and mortality of cardiovascular diseases (CVDs) in low and middle income countries (LMICs) have been increasing, while access to CVDs medicines is suboptimal. We assessed selection of essential ... for the prevention and treatment of CVDs on national essential medicines lists (NEMLs) of LMICs and potential determinants for selection.
Non-communicable diseases (NCDs) pose a substantial threat to many health systems, especially in low-income and middle-income countries (LMICs) where they are already overstretched. In the past few decades, deaths from NCDs in LMICs have spiked, whereas numbers in high-income countries have stabilis...
